Eosinophil activity

Eosinophil activity refers to the physiological activation, migration, and effector functions of eosinophils, a subset of granulocytic white blood cells primary involved in host defense against parasites [StatPearls - Eosinophilia]. This entry is considered 'incorrect' as a target name because it describes a cellular process or phenotype rather than a single molecular target like a protein or receptor [PubMed - PMCID: PMC7304224]. In clinical pharmacology, this activity is modulated by targeting specific signaling molecules that regulate the eosinophil life cycle, most notably the Interleukin-5 (IL-5) pathway [NIH - MedlinePlus]. Biologic therapies such as mepolizumab and reslizumab act by neutralizing the IL-5 cytokine, whereas benralizumab binds to the IL-5 receptor alpha (IL-5RA) to facilitate direct eosinophil depletion through antibody-dependent cell-mediated cytotoxicity [FDA - Fasenra Label]. Pathological eosinophil activity is a central driver of airway inflammation and tissue damage in diseases like eosinophilic asthma and eosinophilic esophagitis, where the release of cytotoxic granules leads to chronic epithelial injury [Journal of Allergy and Clinical Immunology]. Treatment efficacy is typically monitored via blood eosinophil counts, which serve as a critical biomarker for identifying patients most likely to benefit from eosinophil-targeted biologics [ERJ Open Research].

Other names

Eosinophil activationEosinophilic inflammationEosinophil recruitmentEosinophilia

Modulation of eosinophil activity is achieved by neutralizing Interleukin-5 (IL-5) to prevent maturation, blocking the IL-5 receptor alpha (IL-5RA) to induce cell depletion via ADCC, or inhibiting upstream signals like IL-4, IL-13, or TSLP to prevent recruitment and activation.